{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T15:06:48Z","timestamp":1782140808637,"version":"3.54.5"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T00:00:00Z","timestamp":1669593600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011094","name":"Public Health Agency of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011094","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.ijid.2022.11.035","type":"journal-article","created":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T20:34:38Z","timestamp":1669840478000},"page":"162-170","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Effectiveness of COVID-19 vaccines in people living with HIV in British Columbia and comparisons with a matched HIV-negative cohort: a test-negative design"],"prefix":"10.1016","volume":"127","author":[{"given":"Adeleke","family":"Fowokan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4555-7609","authenticated-orcid":false,"given":"Hasina","family":"Samji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3710-5773","authenticated-orcid":false,"given":"Joseph H.","family":"Puyat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveed Z.","family":"Janjua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Wilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7681-7573","authenticated-orcid":false,"given":"Jason","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Troy","family":"Grennan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catharine","family":"Chambers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9137-2461","authenticated-orcid":false,"given":"Abigail","family":"Kroch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4547-714X","authenticated-orcid":false,"given":"Cecilia T.","family":"Costiniuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3368-3499","authenticated-orcid":false,"given":"Curtis L.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann N.","family":"Burchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0323-8885","authenticated-orcid":false,"given":"Aslam","family":"Anis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2022.11.035_bib0001","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0258154","article-title":"Association of pre-existing comorbidities with mortality and disease severity among 167,500 individuals with COVID-19 in Canada: a population-based cohort study","volume":"16","author":"Ge","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.ijid.2022.11.035_bib0002","doi-asserted-by":"crossref","first-page":"e701","DOI":"10.1016\/S2352-3018(21)00240-X","article-title":"Sociodemographic, clinical, and immunological factors associated with SARS-CoV-2 diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective cohort study","volume":"8","author":"Nomah","year":"2021","journal-title":"Lancet HIV"},{"key":"10.1016\/j.ijid.2022.11.035_bib0003","doi-asserted-by":"crossref","first-page":"6283","DOI":"10.1038\/s41598-021-85359-3","article-title":"Epidemiology and outcomes of COVID-19 in HIV-infected individuals: a systematic review and meta-analysis","volume":"11","author":"Ssentongo","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.ijid.2022.11.035_bib0004","doi-asserted-by":"crossref","first-page":"e690","DOI":"10.1016\/S2352-3018(21)00239-3","article-title":"Associations between HIV infection and clinical spectrum of COVID-19: a population level analysis based on US National COVID Cohort Collaborative (N3C) data","volume":"8","author":"Yang","year":"2021","journal-title":"Lancet HIV"},{"key":"10.1016\/j.ijid.2022.11.035_bib0034","doi-asserted-by":"crossref","first-page":"e2005","DOI":"10.1093\/cid\/ciaa1198","article-title":"Risk factors for coronavirus disease 2019 (COVID-19) death in a population cohort study from the Western Cape Province, South Africa","volume":"73","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2022.11.035_bib0005","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1016\/S2352-3018(20)30305-2","article-title":"HIV infection and COVID-19 death: a population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform","volume":"8","author":"Bhaskaran","year":"2021","journal-title":"Lancet HIV"},{"key":"10.1016\/j.ijid.2022.11.035_bib0006","doi-asserted-by":"crossref","first-page":"e1964","DOI":"10.1093\/cid\/ciaa1339","article-title":"Characteristics, comorbidities, and outcomes in a multicenter registry of patients with human immunodeficiency virus and coronavirus disease 2019","volume":"73","author":"Dandachi","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2022.11.035_bib0007","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1186\/s12879-021-06723-2","article-title":"People living with HIV easily lose their immune response to SARS-CoV-2: result from a cohort of COVID-19 cases in Wuhan, China","volume":"21","author":"Liu","year":"2021","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijid.2022.11.035_bib0008","unstructured":"Ong S, Bryce E, British Broadcasting Corporation. How effective are Covid-19 vaccines for people with HIV?, https:\/\/www.bbc.com\/future\/article\/20220419-how-effective-are-covid-19-vaccines-for-people-with-hiv; 2022 [accessed 10 August 2022]."},{"key":"10.1016\/j.ijid.2022.11.035_bib0009","unstructured":"British Columbia Centre for Excellence in HIV\/AIDS. HIV monitoring semi-annual report for British Columbia - second quarter 2022, https:\/\/stophivaids.ca\/qmr\/2022-Q2\/#\/bc; 2022 (accessed 10 August 2022)."},{"key":"10.1016\/j.ijid.2022.11.035_bib0010","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/EDE.0000000000001116","article-title":"The use of test-negative controls to monitor vaccine effectiveness: a systematic review of methodology","volume":"31","author":"Chua","year":"2020","journal-title":"Epidemiology"},{"key":"10.1016\/j.ijid.2022.11.035_bib0011","doi-asserted-by":"crossref","first-page":"n1943","DOI":"10.1136\/bmj.n1943","article-title":"Effectiveness of BNT162b2 and mRNA-1273 Covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe Covid-19 outcomes in Ontario, Canada: test negative design study","volume":"374","author":"Chung","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.ijid.2022.11.035_bib0012","first-page":"ciac290","article-title":"Two-dose SARS-CoV-2 vaccine effectiveness with mixed schedules and extended dosing intervals: test-negative design studies from British Columbia and Quebec","author":"Skowronski","year":"2022","journal-title":"Canada. Clin Infect Dis"},{"key":"10.1016\/j.ijid.2022.11.035_bib0013","doi-asserted-by":"crossref","first-page":"20585","DOI":"10.2807\/1560-7917.ES2013.18.37.20585","article-title":"The test-negative design: validity, accuracy and precision of vaccine efficacy estimates compared to the gold standard of randomised placebo-controlled clinical trials","volume":"18","author":"De Serres","year":"2013","journal-title":"Euro Surveill"},{"key":"10.1016\/j.ijid.2022.11.035_bib0014","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1016\/j.vaccine.2013.02.053","article-title":"The test-negative design for estimating influenza vaccine effectiveness","volume":"31","author":"Jackson","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.ijid.2022.11.035_bib0015","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/aje\/kww064","article-title":"Theoretical basis of the test-negative study design for assessment of influenza vaccine effectiveness","volume":"184","author":"Sullivan","year":"2016","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.ijid.2022.11.035_bib0016","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1097\/EDE.0000000000001251","article-title":"A test-negative design with additional population controls can be used to rapidly study causes of the SARS-CoV-2 epidemic","volume":"31","author":"Vandenbroucke","year":"2020","journal-title":"Epidemiology"},{"key":"10.1016\/j.ijid.2022.11.035_bib0017","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.32760","article-title":"Estimated Effectiveness of COVID-19 vaccines against Omicron or Delta symptomatic infection and severe outcomes","volume":"5","author":"Buchan","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ijid.2022.11.035_bib0018","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41541-022-00452-6","article-title":"Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapy","volume":"7","author":"Brumme","year":"2022","journal-title":"npj Vaccines"},{"key":"10.1016\/j.ijid.2022.11.035_bib0019","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.1016\/j.vaccine.2022.04.090","article-title":"Covid-19 vaccine immunogenicity in people living with HIV-1","volume":"40","author":"Nault","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.ijid.2022.11.035_bib0020","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa2119451","article-title":"Covid-19 vaccine effectiveness against the omicron (B.1.1.529) variant","volume":"386","author":"Andrews","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2022.11.035_bib0021","doi-asserted-by":"crossref","first-page":"e54416","DOI":"10.1371\/journal.pone.0054416","article-title":"Application and validation of case-finding algorithms for identifying individuals with human immunodeficiency virus from administrative data in British Columbia","volume":"8","author":"Nosyk","year":"2013","journal-title":"Canada. PLoS One"},{"key":"10.1016\/j.ijid.2022.11.035_bib0022","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0150176","article-title":"Assessing hepatitis C burden and treatment effectiveness through the British Columbia hepatitis testers cohort (BC-HTC): design and characteristics of linked and unlinked participants","volume":"11","author":"Janjua","year":"2016","journal-title":"PLOS ONE"},{"key":"10.1016\/j.ijid.2022.11.035_bib0023","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/00005650-199801000-00004","article-title":"Comorbidity measures for use with administrative data","volume":"36","author":"Elixhauser","year":"1998","journal-title":"Med Care"},{"key":"10.1016\/j.ijid.2022.11.035_bib0024","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.drugpo.2018.02.001","article-title":"Identifying injection drug use and estimating population size of people who inject drugs using healthcare administrative datasets","volume":"55","author":"Janjua","year":"2018","journal-title":"Int J Drug Policy"},{"key":"10.1016\/j.ijid.2022.11.035_bib0025","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1093\/aje\/kwz268","article-title":"Evaluating the utility of coarsened exact matching for pharmacoepidemiology using real and simulated claims data","volume":"189","author":"Ripollone","year":"2020","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.ijid.2022.11.035_bib0026","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1080\/03610910902859574","article-title":"Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research","volume":"38","author":"Austin","year":"2009","journal-title":"Commun Stat Simul Comput"},{"key":"10.1016\/j.ijid.2022.11.035_bib0027","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1093\/cid\/ciab616","article-title":"Single-dose mRNA vaccine effectiveness against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), including alpha and gamma variants: a test-negative design in adults 70 years and older in British Columbia","volume":"74","author":"Skowronski","year":"2022","journal-title":"Canada. Clin Infect Dis"},{"key":"10.1016\/j.ijid.2022.11.035_bib0028","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/j.cmi.2021.07.031","article-title":"Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1","volume":"27","author":"Levy","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijid.2022.11.035_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101360","article-title":"Sputnik V protection from COVID-19 in people living with HIV under antiretroviral therapy","volume":"46","author":"Gushchin","year":"2022","journal-title":"EClinicalmedicine"},{"key":"10.1016\/j.ijid.2022.11.035_bib0030","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jinf.2021.12.035","article-title":"Short-term effectiveness of COVID-19 vaccines in immunocompromised patients: a systematic literature review and meta-analysis","volume":"84","author":"Marra","year":"2022","journal-title":"J Infect"},{"key":"10.1016\/j.ijid.2022.11.035_bib0031","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1093\/cid\/ciab687","article-title":"Effectiveness of severe acute respiratory syndrome coronavirus 2 messenger RNA vaccines for preventing coronavirus disease 2019 hospitalizations in the United States","volume":"74","author":"Tenforde","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2022.11.035_bib0032","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1080\/14760584.2022.2035222","article-title":"COVID-19 vaccine effectiveness among immunocompromised populations: a targeted literature review of real-world studies","volume":"21","author":"Di Fusco","year":"2022","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.ijid.2022.11.035_bib0033","unstructured":"Public Health Agency of Canada. Estimates of HIV incidence, prevalence and Canada's progress on meeting the 90-90-90 HIV targets, https:\/\/www.canada.ca\/en\/public-health\/services\/publications\/diseases-conditions\/estimates-hiv-incidence-prevalence-canada-meeting-90-90-90-targets-2020.html#a4.3; 2022 [accessed 19 October 2022]."}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971222006245?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971222006245?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T08:11:34Z","timestamp":1761120694000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971222006245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":34,"alternative-id":["S1201971222006245"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2022.11.035","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness of COVID-19 vaccines in people living with HIV in British Columbia and comparisons with a matched HIV-negative cohort: a test-negative design","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2022.11.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}]}}